Braveheart Bio targets up to $318.8M in US IPO

Braveheart Bio, a clinical-stage biopharmaceutical company, has filed for an initial public offering on the Nasdaq Global Market under the ticker symbol NASDAQ: BRVE, according to a press release statement.

The company is offering 18,750,000 shares priced between $15.00 and $17.00 per share, targeting up to $318.8 million in proceeds.

Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel, and Cantor are serving as underwriters for the offering.

You May Also Be Interested In

• Jersey Mike's closes IPO at $23 per share on NYSE
• Coincheck Group N.V. (CNCK) files for 56.5M share offering by selling stockholders
• CarMax executive to depart at year-end with consulting deal